PL372969A1 - Pochodne tiazolu i oksazolu modulujące aktywność PPAR - Google Patents

Pochodne tiazolu i oksazolu modulujące aktywność PPAR

Info

Publication number
PL372969A1
PL372969A1 PL03372969A PL37296903A PL372969A1 PL 372969 A1 PL372969 A1 PL 372969A1 PL 03372969 A PL03372969 A PL 03372969A PL 37296903 A PL37296903 A PL 37296903A PL 372969 A1 PL372969 A1 PL 372969A1
Authority
PL
Poland
Prior art keywords
thiazole
oxazole derivatives
ppar activity
modulate ppar
modulate
Prior art date
Application number
PL03372969A
Other languages
English (en)
Inventor
Xue-Min Cheng
Noe Ouano Erasga
Gary Frederick Filzen
Andrew George Geyer
Chitase Lee
Bharat Kalidas Trivedi
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of PL372969A1 publication Critical patent/PL372969A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/26—Radicals substituted by sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL03372969A 2002-03-07 2003-02-24 Pochodne tiazolu i oksazolu modulujące aktywność PPAR PL372969A1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36240202P 2002-03-07 2002-03-07

Publications (1)

Publication Number Publication Date
PL372969A1 true PL372969A1 (pl) 2005-08-08

Family

ID=27789157

Family Applications (1)

Application Number Title Priority Date Filing Date
PL03372969A PL372969A1 (pl) 2002-03-07 2003-02-24 Pochodne tiazolu i oksazolu modulujące aktywność PPAR

Country Status (29)

Country Link
US (1) US20030207924A1 (pl)
EP (1) EP1482935B1 (pl)
JP (1) JP2005528348A (pl)
KR (1) KR20040091693A (pl)
AP (1) AP2004003124A0 (pl)
AR (1) AR038881A1 (pl)
AT (1) ATE405260T1 (pl)
AU (1) AU2003206059A1 (pl)
BR (1) BR0308277A (pl)
CA (1) CA2478520A1 (pl)
CO (1) CO5601012A2 (pl)
DE (1) DE60323060D1 (pl)
EA (1) EA200400943A1 (pl)
EC (1) ECSP045285A (pl)
ES (1) ES2310650T3 (pl)
HN (1) HN2003000090A (pl)
IS (1) IS7377A (pl)
MA (1) MA27181A1 (pl)
MX (1) MXPA04007564A (pl)
NO (1) NO20044242L (pl)
OA (1) OA12780A (pl)
PA (1) PA8567801A1 (pl)
PE (1) PE20030989A1 (pl)
PL (1) PL372969A1 (pl)
TN (1) TNSN04168A1 (pl)
TW (1) TW200305403A (pl)
UY (1) UY27695A1 (pl)
WO (1) WO2003074050A1 (pl)
ZA (1) ZA200406068B (pl)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6833380B2 (en) 2002-03-07 2004-12-21 Warner-Lambert Company, Llc Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) * 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
US7244763B2 (en) * 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
CN1787817B (zh) * 2003-05-19 2011-09-07 Irm责任有限公司 免疫抑制剂化合物及组合物
EA011010B1 (ru) 2004-02-27 2008-12-30 Эмджен, Инк. Соединения, модулирующие рецептор gpr40, фармацевтическая композиция, способ лечения заболеваний, чувствительных к модулированию рецептора gpr40 (варианты), способ модулирования функции gpr40 (варианты) и способ модулирования циркулирующей концентрации инсулина
JP2007536343A (ja) 2004-05-05 2007-12-13 ノボ　ノルディスク　アクティーゼルスカブ Ｐｐａｒアゴニストとしてのフェノキシ酢酸誘導体
EP1745014B1 (en) 2004-05-05 2011-07-06 High Point Pharmaceuticals, LLC Novel compounds, their preparation and use
US7456164B2 (en) 2004-05-07 2008-11-25 Pfizer, Inc 3- or 4-monosubtituted phenol and thiophenol derivatives useful as H3 ligands
AU2012200214B2 (en) * 2004-05-14 2013-10-24 Emisphere Technologies, Inc. Compounds and compositions for delivering active agents
WO2005115384A2 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Bicyclic, substituted triazoles as modulators of ppar and methods of their preparation
AU2005247473A1 (en) * 2004-05-25 2005-12-08 Metabolex, Inc. Substituted triazoles as modulators of PPAR and methods of their preparation
RU2392274C2 (ru) * 2005-02-25 2010-06-20 Сеул Нэшнл Юниверсити Индастри Фаундейшн Тиазольные производные в качестве лигандов ppar-дельта и способ их получения
US7982050B2 (en) * 2005-05-07 2011-07-19 Seoul National University Industry Foundation Process for preparing ligands of PPARdelta and the intermediate compounds for preparing the same
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
US7943669B2 (en) 2005-06-30 2011-05-17 High Point Pharmaceuticals, Llc Phenoxy acetic acids as PPAR delta activators
EP1916234B1 (en) * 2005-07-29 2014-11-12 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
EP1924546A1 (en) 2005-09-14 2008-05-28 Amgen, Inc Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
EA201101084A1 (ru) 2005-12-22 2012-04-30 ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи Феноксиуксусные кислоты в качестве активаторов ppar дельта
JP2009132620A (ja) * 2006-03-07 2009-06-18 Astellas Pharma Inc フェニルチアゾール誘導体
JP2009529512A (ja) 2006-03-09 2009-08-20 ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー 新規な化合物、それらの製造法、及び使用法
US7687526B2 (en) 2006-09-07 2010-03-30 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
AU2007293028B2 (en) 2006-09-07 2012-05-31 Amgen Inc. Heterocyclic GPR40 modulators
CA2683751C (en) 2007-04-16 2013-01-08 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators
KR20100090249A (ko) 2007-10-10 2010-08-13 암젠 인크 치환된 비페닐 ｇｒｐ４０ 조절제
WO2009078981A2 (en) * 2007-12-13 2009-06-25 Sri International Ppar-delta ligands and methods of their use
RU2527177C2 (ru) 2007-12-20 2014-08-27 Энвиво Фармасьютикалз, Инк. Четырехзамещенные бензолы
US8450522B2 (en) 2008-03-06 2013-05-28 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
US8748462B2 (en) 2008-10-15 2014-06-10 Amgen Inc. Spirocyclic GPR40 modulators
EP2540711A4 (en) * 2010-02-25 2014-01-22 Snu R&Db Foundation Selenium-Zolderivate with ligand for the activation of the peroxisome-proliferator-activated receptor (PPAR), preparation method therefor and use of the chemical compounds
ES2811087T3 (es) 2013-09-09 2021-03-10 Vtv Therapeutics Llc Uso de agonistas de PPAR-delta para tratar la atrofia muscular
WO2023147309A1 (en) 2022-01-25 2023-08-03 Reneo Pharmaceuticals, Inc. Use of ppar-delta agonists in the treatment of disease

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5859051A (en) * 1996-02-02 1999-01-12 Merck & Co., Inc. Antidiabetic agents
IL128600A0 (en) * 1996-08-19 2000-01-31 Japan Tobacco Inc Propionic acid derivatives and pharmaceutical compositions containing them
GB9914977D0 (en) * 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
WO2002050047A1 (en) * 2000-12-20 2002-06-27 Glaxo Group Limited Substitued oxazoles and thiazoles as hppar alpha agonists
GB0031107D0 (en) * 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0111523D0 (en) * 2001-05-11 2001-07-04 Glaxo Group Ltd Chemical compounds
EA200400011A1 (ru) * 2001-06-07 2004-06-24 Эли Лилли Энд Компани Модуляторы рецепторов, активируемых пролифераторами пероксисом (prar)

Also Published As

Publication number Publication date
EP1482935A1 (en) 2004-12-08
AP2004003124A0 (en) 2004-09-30
PA8567801A1 (es) 2003-11-12
EP1482935B1 (en) 2008-08-20
TW200305403A (en) 2003-11-01
BR0308277A (pt) 2004-12-28
OA12780A (en) 2006-07-07
JP2005528348A (ja) 2005-09-22
MA27181A1 (fr) 2005-01-03
NO20044242L (no) 2004-10-06
US20030207924A1 (en) 2003-11-06
WO2003074050A1 (en) 2003-09-12
PE20030989A1 (es) 2003-11-29
AU2003206059A1 (en) 2003-09-16
ECSP045285A (es) 2004-10-26
UY27695A1 (es) 2003-10-31
EA200400943A1 (ru) 2005-02-24
DE60323060D1 (de) 2008-10-02
IS7377A (is) 2004-07-29
CO5601012A2 (es) 2006-01-31
KR20040091693A (ko) 2004-10-28
HN2003000090A (es) 2004-05-05
MXPA04007564A (es) 2004-11-10
TNSN04168A1 (fr) 2007-03-12
ES2310650T3 (es) 2009-01-16
AR038881A1 (es) 2005-02-02
ATE405260T1 (de) 2008-09-15
CA2478520A1 (en) 2003-09-12
ZA200406068B (en) 2005-09-06

Similar Documents

Publication Publication Date Title
IL163768A0 (en) Thiazole and oxazole derivatives that modulate ppar activity
AU2003207914A1 (en) Substituted thiazoles and oxazoles that modulate ppar activity
NO20044242L (no) Tiazol og oksazolderivater som modulerer PPAR-aktivitet
IL166334A0 (en) Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity
PL372123A1 (pl) Pochodne tiazolu
AU2003302763A8 (en) Insecticidal aminothiazole derivatives
PL371429A1 (pl) Pochodne tiazolu o aktywności antagonistycznej, agonistycznej lub częściowo agonistycznej wobec CB1
DK1206472T3 (da) Oxazol- og thiazolderivater som neutrophinproduktions/sekretionsfremmende middel
IL161623A0 (en) Nicotin-or isonicotin benzothiazole derivatives
IL146634A0 (en) Thiazole and oxazole derivatives and their pharmaceutical use
DE60226063D1 (en) Benzothiazole derivative
PL365797A1 (pl) Pochodne tiazolu do leczenia zaburzeń związanych z PPAR
AU2003287965A8 (en) Modulation of peroxisome proliferator activated receptors activity
HRP20020962A2 (en) Benzothiazole derivatives
ZA200606027B (en) Thiazole derivative
AU2003296404A1 (en) Heterocyclic ppar modulators
IL206050A0 (en) Oxazole derivatives of tetracyclines
PL375416A1 (pl) Pochodne tiazolu
AU2001248820A1 (en) Thiazole and oxazole derivatives
DE60310750D1 (de) Einheit zum überführen und zum einstellen der zwischenräume von gegenständen
AU2003296481A1 (en) Aminoalkyl thiazole derivatives as kcnq modulators
ATE309242T1 (de) Benzothiazole
DK1173437T3 (da) Thiazolidinindionderivat og dets anvendelse som antidiabetisk middel
NO20035652L (no) Tiaziner og tiazoler som materialbeskyttelsesmidler
HK1077300A (en) Benzothiazole derivatives having beta-2-adrenoreceptor agonist activity

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)